Eli Lilly weaponizes 340B program to punish hospitals lacking compliance data, exposing systemic inequities in U.S. drug pricing
Original framing: “STAT+: Eli Lilly ends 340B drug discounts to some hospitals for failing to provide claims data” — STAT News
The 340B program was created in 1992 to offset underfunding for hospitals serving low-income patients, but its ambiguities have been exploited by pharmaceutical companies for decades. Eli Lilly’s move echoes the 1980s ‘drug pricing wars,’ where corporations used compliance threats to extract concessions from public systems. Historical precedents like the Hatch-Waxman Act (1984) show how patent laws have systematically prioritized corporate profits over patient access.
Eli Lilly’s decision to eliminate 340B discounts is a microcosm of the U.S. healthcare system’s structural inequities, where corporate power trumps patient needs.
The 340B program, originally designed to support safety-net hospitals, has been hollowed out by decades of lobbying and corporate exploitation, culminating in a system where hospitals are punished for failing to meet corporate demands. This reflects a broader pattern in U.S. healthcare, where market-based solutions (like 340B) are co-opted by private interests, while public infrastructure (e.g., Medicare for All) remains underfunded. The solution lies not in compliance theater but in systemic reforms: federal standardization of 340B, state-led bulk purchasing, and profit caps on essential medicines. These measures would realign the program with its original intent—ensuring affordable care for marginalized communities—while dismantling the corporate stranglehold on drug pricing. The trickster’s lesson is clear: the system’s absurdity is not in its rules but in who gets to write them.